177Lu	Lutetium-177
18F-DCFPyL	18F-labelled Prostate-Specific Membrane Antigen Ligand
18F-FDG	18F-Fluorodeoxyglucose
18F-PSMA-1007	18F-labelled Prostate-Specific Membrane Antigen Ligand
68Ga-PSMA	68Ga-labelled Prostate-Specific Membrane Antigen Ligand
ADT	Androgen Deprivation Therapy
APCCC	Advanced Prostate Cancer Consensus Conference
BCR	Biochemical Recurrence
CT	Biochemical Recurrence
CTV	Computed Tomography
EANM	European Association of Nuclear Medicine
EMA	European Medicines Agency
FDG	Fluorodeoxyglucose
FDA	Fluorodeoxyglucose
FOLH1	Folate Hydrolase 1
GTV	Gross Tumor Volume
HR	Hazard Ratio
iADT	Intermittent Androgen Deprivation Therapy
iPSMA	Imaging Prostate-Specific Membrane Antigen
Lutetium-PSMA	Lutetium-labelled Prostate-Specific Membrane Antigen Ligand
MDT	Metastasis-Directed Therapy
mCRPC	Metastatic Castration-Resistant Prostate Cancer
miTNM	Molecular Imaging TNM Classification
MRI	Magnetic Resonance Imaging
NCCN	National Comprehensive Cancer Network
OAR	Organs At Risk
OS	Overall Survival
PCa	Prostate Cancer
PET	Positron Emission Tomography
PPP	PSMA-PET/CT Progression
PPV	Positive Predictive Value
PROMISE	Prostate Cancer Molecular Imaging Standardized Evaluation
PSA	Prostate-Specific Antigen
PSMA	Prostate-Specific Membrane Antigen
PSMA-RLT	PSMA-Targeted Radioligand Therapy
PTV	Planning Target Volume
RECIP	Response Evaluation Criteria in PSMA-PET/CT
RP	Radical Prostatectomy
rPFS	Radiographic Progression-Free Survival
RT	Radiotherapy
SABR	Stereotactic Ablative Radiotherapy
SBRT	Stereotactic Body Radiation Therapy
SNMMI	Society of Nuclear Medicine and Molecular Imaging
SOC	Standard of Care
SRT	Salvage Radiotherapy
SUV	Standardized Uptake Value
SUVmax	Maximum Standardized Uptake Value
SUVmean	Mean Standardized Uptake Value
TBR	Tumor-to-Background Ratio
TE-FS	Treatment Escalation-Free Survival
TNM	Tumor, Node, Metastasis Classification